AZNCF Healthcare

AstraZeneca PLC

$179.39
-1.97% ($-3.61)
Valuation Metrics
P/E Trailing --
P/E Forward --
PEG Ratio --
Market Cap --
Price Target --
Balance Sheet
D/E Ratio --
Current Ratio --
Cash --
Total Debt --
Net Cash --
Profitability
Gross Margin --
Operating Margin --
Net Margin --
ROE --
FCF --
Scores
GF Score --
Altman Z-Score --
Piotroski F-Score --
Div. Yield --
Analyst Rating --
Analysis & Conclusion BEARISH
STRONG_SELL

STRONG SELL: Metrics within normal ranges.

Recent News
Tempus AI's Key 2025 Milestones Continue to Gain Industry Attention

TEM hits $1.1B TCV, signs 70+ pharma data deals and posts its first positive adjusted EBITDA in Q3 2025 as adoption accelerates.

Zacks •
AstraZeneca PLC (AZN) Gains After Successful Saphnelo Trial

We recently compiled a list of the Top 10 Oncology Stocks to Buy Now. AstraZeneca PLC is placed fourth on our list among the best cancer stocks. TheFly reported on …

Insider Monkey •
The Bull Case For Illumina (ILMN) Could Change Following Its Billion Cell Atlas Pharma Alliance

Earlier in January 2026, Illumina announced the Billion Cell Atlas alliance with AstraZeneca, Merck, and Eli Lilly, alongside new AI‑enabled genomics and multiomics platforms that integrate CRISPR, single-cell sequencing, and …

Simply Wall St. •
Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

As weight loss drugs move from injections to pills, this thematic ETF provides broad exposure for investors looking to profit from the industry’s next leg up.

MarketBeat •
AstraZeneca’s Subcutaneous Saphnelo Shows Significant Disease Reduction in Landmark Lupus Trial

AstraZeneca (NASDAQ:AZN) is one of the best future stocks to buy for the long term. On January 6, Barclays analyst James Gordon raised the firm’s price target on AstraZeneca to …

Insider Monkey •
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy

The acquisition gives AstraZeneca full global control of the therapy’s development, manufacturing and commercialisation.

Pharmaceutical Technology •
Health Care Roundup: Market Talk

1203 ET – Big European pharmaceutical stocks have rallied in recent weeks, which makes them vulnerable should companies’ 2026 guidance disappoint, Bank of America analysts say in a note. The …

The Wall Street Journal •
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading

Letitia James accused Robert Kramer of selling his shares in Emergent before disclosing contamination issues in its production of the Covid-19 vaccine.

The Wall Street Journal •
Emergent BioSolutions' Former CEO Sued for Insider Trading by New York Attorney General

Emergent BioSolutions (EBS) former CEO Robert Kramer was sued by New York Attorney General Letitia J

MT Newswires •
What Makes AstraZeneca (AZN) a Strong Growing Company?

Oakmark Funds, advised by Harris Associates, released its “Oakmark International Fund” fourth-quarter 2025 investor letter. It is a diversified fund that focuses on long-term capital appreciation by investing in common …

Insider Monkey •